May 16, 2008 — Phenomix Corporation announced that PHX1149, a dipeptidyl peptidase-4 (DPP-4) inhibitor, demonstrated positive results in a Phase 2b clinical trial for the treatment of Type 2 diabetes.The 12-week, double-blind, placebo-controlled clinical trial involving 422 randomized patients compared PHX1149 in once-daily oral doses of 200 milligrams and 400 milligrams to placebo. Patients were allowed to continue selected anti-diabetic drugs, either metformin or a thiazolidinedione, or a combination of the two, at a constant dose during the trial. PHX1149 demonstrated statistically significant reductions in hemoglobin A1c (HbA1c) in both the 200 milligram and 400 milligram dose groups... Phenomix's Press Release -
